Skip to content
Est. 1998 proudly celebrating 27 years of standing behind American companies
American Origin Unverified This profile is unclaimed and has not been independently reviewed. Claim & get verified

Ultragenyx Pharmaceutical Inc. (RARE)

$15.65 -1.88% NASDAQ: RARE · 15-min delayed
  • NOVATO, California
  • Public · NASDAQ: RARE
  • 1,371 employees
$2.6BMarket cap
$673.0MRevenue · FY2025
-$575.0MNet income
1,371Employees
RARENASDAQ
2014IPO

About Ultragenyx Pharmaceutical Inc.

Ultragenyx Pharmaceutical Inc is a USA-based biopharmaceutical company. The company identifies, acquires, develops, and commercializes novel products for the treatment of serious, rare, and ultra-rare diseases, with a focus on debilitating genetic conditions. Its medicine portfolio includes Crysvita, Dojolvi, and Mepsevii. Crysvita is indicated for the treatment of X-linked hypophosphatemia (XLH) in adult and pediatric patients aged one year and older. Mepsevii is indicated for pediatric and adult patients for the treatment of Mucopolysaccharidosis VII. The company operates across North America, Latin America, Europe, the Middle East and Africa, and Asia-Pacific, with the majority of its revenue generated from North America.

This profile is unclaimed. An authorized representative can claim it free to control the page and activate the embeddable Verified badge.

Reported figures

Financial summary

Revenue FY2025
$673.0M
Net income
-$575.0M
Total assets
$1.5B
Market cap
$2.6B

Source: SEC EDGAR · updated Jun 7, 2026

NASDAQ: RARE
$15.65 -1.88%

15-minute delayed · data by Polygon.io

Past year · hover for prices

$12.88 $36.54

52-week range

Market cap
$2.6B
Shares outstanding
169.3M
Open
—
Day range
–
Prev close
—
Volume
—
IPO date
Jan 31, 2014

Ultragenyx Pharmaceutical Inc. (RARE) Stock Price

  • Reported a net loss of $575.0M in FY2025.
  • Trading 57% below its 52-week high.

Automatically generated from public filings and market data. Informational only — not investment advice or a recommendation to buy or sell any security.

No reviews yet. Be the first to review Ultragenyx Pharmaceutical Inc..

Write a review
Newsroom

News about Ultragenyx Pharmaceutical Inc.

News & sentiment via Polygon.io

FAQ

Ultragenyx Pharmaceutical Inc.: frequently asked questions

Is Ultragenyx Pharmaceutical Inc. an American company?

Ultragenyx Pharmaceutical Inc. is a US-based company headquartered in Novato, California, listed in the americancompanies.com directory of American companies. Its American-origin credentials have not yet been independently verified.

Where is Ultragenyx Pharmaceutical Inc. headquartered?

Ultragenyx Pharmaceutical Inc. is headquartered in Novato, California, United States.

Is Ultragenyx Pharmaceutical Inc. publicly traded?

Yes — Ultragenyx Pharmaceutical Inc. is a publicly traded company. Its stock trades under the ticker symbol RARE on the NASDAQ.

What does Ultragenyx Pharmaceutical Inc. do?

Ultragenyx Pharmaceutical Inc. is an American Pharmaceuticals company in the Health & Beauty sector.

Explore

Similar companies

Browse all →